Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Sabrina BaltschukatBarbara Schacher EngstlerAlan HuangHuai-Xiang HaoAngela TamHui Qin WangJinsheng LiangMatthew T DiMareHyo-Eun Carrie BhangYouzhen WangPascal FuretWilliam R SellersFrancesco HofmannJoseph SchoepferRalph TiedtPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Activity of capmatinib in preclinical models is associated with a small number of plausible genomic features. The low fraction of cancer models that respond to capmatinib as a single agent suggests that the implementation of patient selection strategies based on these biomarkers is critical for clinical development. Capmatinib is also a rational combination partner for other kinase inhibitors to combat MET-driven resistance.